SCHEMBL6841244

SCHEMBL6841244

COc1cc(NC(=O)c2cccc(CCl)c2)cc(OC)c1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.65
ATM Q13315 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 2/20 0.54
ALDH1A1 P00352 1/20 0.54
POLB P06746 1/20 0.54
GFER P55789 1/20 0.54
STAT3 P40763 1/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
RAB9A P51151 3/20 0.51
SMO Q99835 1/20 0.51
NAMPT P43490 1/20 0.51
NPC1 O15118 2/20 0.50
GAA P10253 1/20 0.50
MAPK1 P28482 1/20 0.50
P4HTM Q9NXG6 1/20 0.50
ABCB1 P08183 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30958899 0.81 ATM (0.89) ATMSMN1; SMN2MAPTALDH1A1POLB
SCHEMBL6502527 0.81 RXFP1 (0.74) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL10855237 0.80 ABCB1 (0.68) LMNAATMSMN1; SMN2MAPTALDH1A1
Iodide SCHEMBL30758622 0.79 ATM (0.86) ATMSMN1; SMN2MAPTALDH1A1POLB
SCHEMBL2896309 0.79 RAB9A (0.65) ATMSMN1; SMN2MAPTALDH1A1MEN1
SCHEMBL22628681 0.78 ATM (0.62) LMNAATMSMN1; SMN2MAPTALDH1A1
SCHEMBL29712456 0.78 HDAC8 (0.61) LMNASMN1; SMN2POLBMEN1KMT2A
SCHEMBL4068853 0.78 HDAC8 (0.61) LMNASMN1; SMN2POLBMEN1KMT2A
SCHEMBL16681578 0.77 ATM (0.68) LMNAATMSMN1; SMN2MAPTALDH1A1
SCHEMBL6349892 0.76 ATM (0.68) LMNAATMSMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA LMNA 4001/4885ATM 540/4885SMN1; SMN2 4682/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA LMNA 4001/4885ATM 540/4885SMN1; SMN2 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.